<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03205072</url>
  </required_header>
  <id_info>
    <org_study_id>E7114</org_study_id>
    <nct_id>NCT03205072</nct_id>
  </id_info>
  <brief_title>POCS in Liver Transplantation Patients</brief_title>
  <official_title>Per-Oral Cholangioscopy in Liver Transplantation Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multi-center, non-randomized, observational, consecutive case series, which&#xD;
      will compare Endoscopic Retrograde Cholangiopancreatoscopy (ERCP) and cholangioscopy with Spy&#xD;
      Glass Digital System (DS) procedure at 5-10 centers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to demonstrate the clinical utility of cholangioscopy with Spy&#xD;
      Glass Digital System (DS) in cadaveric donor or live donor liver transplantation patients who&#xD;
      are referred for ERCP in the setting of a clinical suspicion of post liver transplant bile&#xD;
      duct stricture(s). A secondary study objective is to generate a hypothesis for a randomized&#xD;
      controlled trial comparing ERCP alone to ERCP with Per- Oral Cholangioscopy (POCS) in&#xD;
      patients referred for ERCP post liver transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 25, 2018</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Actual">February 28, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Impact of Per-Oral Cholangioscopy on Patient Management</measure>
    <time_frame>12 Months</time_frame>
    <description>To evaluate the impact of the addition of POCS to same setting ERCP on the recommended management of post-liver transplantation biliary complications.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical Success</measure>
    <time_frame>12 Months</time_frame>
    <description>Ability to visualize the duct/lesion of interest and, if applicable, ability to obtain POCS-guided biopsy adequate for histopathology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>12 Months</time_frame>
    <description>Serious Adverse Events (SAEs) including severity, onset, time to resolution, required interventions, relatedness to endoscopic devices and/or procedures and hospitalizations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of biliary re-interventions</measure>
    <time_frame>12 Months</time_frame>
    <description>Re-interventions may include but are not limited to repeat ERCP, repeat POCS, ultrasonography, stent exchanges, balloon dilations and liver biopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Management</measure>
    <time_frame>3 and 12 Months</time_frame>
    <description>Confirmation at 3 months and at 12 months that recommended management at the index procedures was adequate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between endoscopic findings on POCS visualization</measure>
    <time_frame>12 Months</time_frame>
    <description>Relationship between endoscopic findings on POCS visualization during index procedure and refractory biliary strictures during follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation</measure>
    <time_frame>12 Months</time_frame>
    <description>Evaluation by surgeon of whether or not POCS impacted patient management post procedure.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">42</enrollment>
  <condition>Liver Transplant; Complications</condition>
  <arm_group>
    <arm_group_label>ERCP &amp; Spy Glass DS</arm_group_label>
    <description>Patients with cadaveric donor or live donor liver transplantation referred for ERCP in the setting of a clinical suspicion of post liver transplant bile duct strictures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spy Glass DS</intervention_name>
    <description>The SpyScope™ DS Access and Delivery Catheter (SpyScope™ DS Catheter) is a sterile, single-use endoscope that enables access and delivery of accessories to targeted pancreaticobiliary anatomy and displays live video when connected to a Spy Glass DS Digital Controller.</description>
    <arm_group_label>ERCP &amp; Spy Glass DS</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biopsies if needed at the discretion of the PI.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cadaveric donor or live donor liver transplantation patients referred for ERCP in the&#xD;
        setting of a clinical suspicion of post-liver transplant bile duct stricture(s).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Liver transplantation at least 1 month prior to POCS procedure&#xD;
&#xD;
          2. Abnormal Liver Function Tests (LFTs) and/or biliary obstructive symptoms&#xD;
&#xD;
          3. Prior cross sectional imaging (MRI and/or US and/or CT)&#xD;
&#xD;
          4. Suspicion of anastomotic biliary stricture(s)&#xD;
&#xD;
          5. Diameter of bile ducts deemed sufficient to accommodate cholangioscopy system based on&#xD;
             baseline imaging&#xD;
&#xD;
          6. Willing and able to provide a written informed consent to participate in the study&#xD;
&#xD;
          7. Willing and able to comply with study procedures and follow-up schedule&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindication for an ERCP per local standard of practice&#xD;
&#xD;
          2. Deemed contraindicated for POCS per local standard of practice&#xD;
&#xD;
          3. Prior biliary treatment of biliary anastomotic stricture&#xD;
&#xD;
          4. &lt; 18 years old&#xD;
&#xD;
          5. Documented life expectancy of less than 12 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amrita Sethi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduardo De Moura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital das Clinicas University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adam Slivka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andres Cardenas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco Bruno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York Presbyterian Hospital CUMC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas</name>
      <address>
        <city>São Paulo</city>
        <zip>05403</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 26, 2017</study_first_submitted>
  <study_first_submitted_qc>June 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ERCP</keyword>
  <keyword>Per-Oral Cholangioscopy</keyword>
  <keyword>Liver Transplantation</keyword>
  <keyword>Spy Glass</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

